NCT00360906

Timeline

Start date

Dec 1, 2004

Primary completion

—

Completion date

Jul 1, 2008

First posted

—

Last posted

—

Enrollment

100

Arms / groups

— / —

Source

AACT · pre-existing

Sponsors

• University of BergenLead sponsor
• University of BergenStudy chair
• Oslo Metropolitan UniversityOverall official - principal investigator
• Buskerud HospitalOverall official - principal investigator
• Fredrikstad HospitalOverall official - principal investigator
• Norwegian University of Science and TechnologyOverall official - principal investigator
• Haugesund HospitalOverall official - principal investigator
• Lillehammer HospitalOverall official - principal investigator
• Nordland HospitalOverall official - principal investigator
• University of OsloOverall official - principal investigator
• University of StavangerOverall official - principal investigator
• Telemark Hospital TrustOverall official - principal investigator
• Pronova BioPharmaCollaborator
• The Multiple Sclerosis National Competence CentreCollaborator
• The Norwegian Multiple sclerosis SocietyCollaborator
• SeronoCollaborator
• Arendal HospitalOverall official - principal investigator
• AmershamCollaborator
• Molde University CollegeOverall official - principal investigator

Drugs studied

• omega-3 fatty acids

Indications studied

• Multiple Sclerosis, Relapsing-Remitting